Altimmune, Inc. ALT
Set alert
2.04 USD -0.10 -4.67%
At close · Oct 30
2.07 +0.03 +1.47%
After hours · Oct 30, 7:12 PM ET
1.99 Day range 2.13
2.04 52-week range 6.18
- YTD
- -43.49%
- 1 year
- -49.88%
- Open
- 2.10
- Prev close
- 2.14
- Mkt cap
- 396.82M
- Vol
- 3.52M
- Avg vol
- 4.05M
- EPS
- -0.76
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.99
- High
- 2.13
- Forward P/E
- -5.14
- Beta
- 0.07
- Short ratio
- 5.81
- Inst. own
- 56.68%
- Dividend
- 0.00
- Ex-div date
- Jan 19, 2017
- 50-d avg
- 7.91
- 200-d avg
- 7.41
- 1y target
- 22.86
5D chart
Signals (63)
| Name | Time | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 30, 2:30 PM | 1 day ago |
| MACD: Sell Signal | Oct 30, 2:15 PM | 1 day ago |
| RSI: Oversold | Oct 30, 2:10 PM | 1 day ago |
| RSI: Oversold | Oct 30, 1:50 PM | 1 day ago |
| MACD: Buy Signal | Oct 30, 1:25 PM | 1 day ago |
| MACD: Sell Signal | Oct 30, 12:45 PM | 1 day ago |
| MACD: Buy Signal | Oct 30, 12:40 PM | 1 day ago |
| MACD: Sell Signal | Oct 30, 12:35 PM | 1 day ago |
| SMA: Bearish | Oct 30, 12:30 PM | 1 day ago |
| MACD: Buy Signal | Oct 30, 12:25 PM | 1 day ago |
| MACD: Sell Signal | Oct 30, 11:40 AM | 1 day ago |
| RSI: Oversold | Oct 30, 11:40 AM | 1 day ago |
| MACD: Buy Signal | Oct 30, 10:35 AM | 1 day ago |
| RSI: Oversold | Oct 30, 9:40 AM | 1 day ago |
| MACD: Sell Signal | Oct 30, 9:30 AM | 1 day ago |
| RSI: Oversold | Oct 30, 9:30 AM | 1 day ago |
| MACD: Buy Signal | Oct 29, 3:05 PM | 2 days ago |
| RSI: Overbought | Oct 29, 12:25 PM | 2 days ago |
| RSI: Overbought | Oct 29, 11:50 AM | 2 days ago |
| MACD: Sell Signal | Oct 29, 11:45 AM | 2 days ago |
| MACD: Buy Signal | Oct 29, 11:20 AM | 2 days ago |
| RSI: Overbought | Oct 29, 11:05 AM | 2 days ago |
| MACD: Sell Signal | Oct 29, 10:50 AM | 2 days ago |
| RSI: Overbought | Oct 28, 3:55 PM | 3 days ago |
| SMA: Bullish | Oct 28, 3:40 PM | 3 days ago |
| MACD: Buy Signal | Oct 28, 3:40 PM | 3 days ago |
| SMA: Bullish | Oct 28, 3:30 PM | 3 days ago |
| SMA: Bearish | Oct 28, 2:20 PM | 3 days ago |
| MACD: Sell Signal | Oct 28, 2:10 PM | 3 days ago |
| SMA: Bearish | Oct 28, 2:05 PM | 3 days ago |
| MACD: Buy Signal | Oct 28, 1:20 PM | 3 days ago |
| MACD: Sell Signal | Oct 28, 1:15 PM | 3 days ago |
| MACD: Buy Signal | Oct 28, 1:05 PM | 3 days ago |
| SMA: Bullish | Oct 28, 12:50 PM | 3 days ago |
| MACD: Sell Signal | Oct 28, 12:30 PM | 3 days ago |
| SMA: Bullish | Oct 28, 11:15 AM | 3 days ago |
| MACD: Buy Signal | Oct 28, 11:15 AM | 3 days ago |
| SMA: Bullish | Oct 28, 11:10 AM | 3 days ago |
| RSI: Oversold | Oct 28, 10:30 AM | 3 days ago |
| SMA: Bearish | Oct 28, 10:10 AM | 3 days ago |
| SMA: Bearish | Oct 28, 10:10 AM | 3 days ago |
| MACD: Sell Signal | Oct 28, 10:10 AM | 3 days ago |
| MACD: Buy Signal | Oct 28, 9:40 AM | 3 days ago |
| MACD: Sell Signal | Oct 28, 9:30 AM | 3 days ago |
| MACD: Buy Signal | Oct 27, 2:00 PM | 4 days ago |
| MACD: Sell Signal | Oct 27, 1:50 PM | 4 days ago |
| MACD: Buy Signal | Oct 27, 1:30 PM | 4 days ago |
| SMA: Bullish | Oct 27, 1:20 PM | 4 days ago |
| SMA: Bearish | Oct 27, 11:50 AM | 4 days ago |
| MACD: Sell Signal | Oct 27, 11:50 AM | 4 days ago |
| MACD: Buy Signal | Oct 27, 11:45 AM | 4 days ago |
| MACD: Sell Signal | Oct 27, 11:05 AM | 4 days ago |
| SMA: Bearish | Oct 27, 11:00 AM | 4 days ago |
| RSI: Overbought | Oct 27, 10:50 AM | 4 days ago |
| RSI: Overbought | Oct 27, 9:45 AM | 4 days ago |
| SMA: Bullish | Oct 26, 3:55 PM | 5 days ago |
| MACD: Buy Signal | Oct 26, 3:45 PM | 5 days ago |
| RSI: Oversold | Oct 26, 3:40 PM | 5 days ago |
| RSI: Oversold | Oct 26, 3:30 PM | 5 days ago |
| RSI: Oversold | Oct 26, 2:55 PM | 5 days ago |
| MACD: Sell Signal | Oct 26, 1:25 PM | 5 days ago |
| MACD: Buy Signal | Oct 26, 12:20 PM | 5 days ago |
| SMA: Bullish | Oct 26, 11:10 AM | 5 days ago |
News
4 days ago globenewswire.com
Altimmune Appoints Peter Greenleaf and Alex Howarth, Two Leading Biotech Executives, to Board of Directors to Support Its Strategic Evolution
Board appointments align with successful transition to late-stage clinical Company developing pemvidutide as a differentiated liver franchise with multiple potential indications As part of this…
1 week ago gurufocus.com
Xencor Presents Phase 1 Dose Selection Data for XmAb819, a Potential First-in-Class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Patients With Advanced Clear Cell Renal Cell Carcinoma and
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, tod